SEARCH

SEARCH BY CITATION

References

  • 1
    Heyerdahl T. Aku-Aku (The secrets of Easter Island). London:Allen & Unwin, 1958.
  • 2
    Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28:721726. MEDLINE
  • 3
    Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol 1977; 55:4851.
  • 4
    Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17:609610.
  • 5
    Calne RY, Lim S, Saaman A, Collier DSJ, Pollard SG, White DJ, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2:227. MEDLINE
  • 6
    Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 358:7073. MEDLINE
  • 7
    Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253:905909. MEDLINE
  • 8
    Abraham RT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10:330336. MEDLINE
  • 9
    Sabers C, Martin M, Brunn G, Williams J, Dumont F, Wiederrecht G, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270:815822. MEDLINE
  • 10
    Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell 1996; 86:517520. MEDLINE
  • 11
    Sabatini D, Erdjument-Bromage H, Lui M, Tempst P, Snyder S. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78:3543. MEDLINE
  • 12
    Burnett P, Barrow R, Cohen N, Snyder S, Sabatini D. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 1998; 95:14321437. MEDLINE
  • 13
    Chiu M, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 1994; 91:1257412578. MEDLINE
  • 14
    Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14:483510. MEDLINE
  • 15
    Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: A review. J Am Soc Nephrol 1999; 10:13661380. MEDLINE
  • 16
    Rovira P, Mascarell L, Truffa Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem 2000; 7:673692. MEDLINE
  • 17
    Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action of immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31:335340. MEDLINE
  • 18
    Jefferies H, Fumagalli S, Dennis P, Reinhard C, Pearson R, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997; 16:36933704. MEDLINE
  • 19
    Alessi D, Kozlowski M, Weng Q, Morrice N, Avruch J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol 1998; 8:6981. MEDLINE
  • 20
    Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999; 253:100109. MEDLINE
  • 21
    Hamilton GS, Steiner JP. Immunophilins: Beyond immunosuppression. J Med Chem 1998; 41:51195143. MEDLINE
  • 22
    Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64:3642. MEDLINE
  • 23
    Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin. Pharm Res 1998; 15:16661672. MEDLINE
  • 24
    Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999; 27:627632. MEDLINE
  • 25
    Soldin SJ. Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. Clin Biochem 1998; 31:381384. MEDLINE
  • 26
    Trepanier D, Gallant H, Legatt D, Yatscoff R. Rapamycin: Distribution, pharmacokinetics and therapeutic range investigations: An update. Clin Biochem 1998; 31:345351. MEDLINE
  • 27
    Schmidbauer G, Hancock W, Wasowska B, Badger A, Kupiec-Weglinski J. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994; 57:933941. MEDLINE
  • 28
    Boehler T, Waiser J, Budde K, Lichter S, Jauho A, Fritsche L, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30:21952197. MEDLINE
  • 29
    Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris R. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59:390395. MEDLINE
  • 30
    Morris R, Huang X, Gregory C, Billingham M, Rowan R, Shorthouse R, et al. Studies in experimental models of chronic rejection: Use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27:20682069. MEDLINE
  • 31
    Morris R, Cao W, Huang X, Gregory C, Billingham M, Rowan R, et al. Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: Evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc 1995; 27:430431. MEDLINE
  • 32
    Nair R, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R, et al. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997; 29:614615. MEDLINE
  • 33
    Zhu J, Wu J, Frizell E, Liu S, Bashey R, Rubin R, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117:11981204. MEDLINE
  • 34
    Poston R, Billingham M, Hoyt E, Pollard J, Shorthouse R, Morris R, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100:6774. MEDLINE
  • 35
    Ikonen T, Gummert J, Hayase M, Honda Y, Hausen B, Christians U, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70:969975. MEDLINE
  • 36
    Ikonen T, Gummert J, Serkova N, Hayase M, Honda Y, Kobayase Y, et al. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: Trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int 2000; 13(suppl 1):S314S320. MEDLINE
  • 37
    Fahrni J, Berry G, Morris R, Rosen G. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation 1997; 63:533537. MEDLINE
  • 38
    Dai Z, Konieczny B, Baddoura F, Lakkis F. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998; 161:16591663. MEDLINE
  • 39
    Shi Y, Frankel A, Radvanyi L, Penn L, Miller R, Mills G. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55:19821988. MEDLINE
  • 40
    Li Y, Zheng X, Li X, Zand M, Strom T. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66:13871388. MEDLINE
  • 41
    Umemura A, Monaco A, Maki T. Donor T cells are not required for induction of allograft tolerance in mice treated with antilymphocyte serum, rapamycin, and donor bone marrow cells. Transplantation 2000; 70:10051009. MEDLINE
  • 42
    Hale D, Gottschalk R, Maki T, Monaco A. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 1998; 65:473479. MEDLINE
  • 43
    Wells A, Li X, Li Y, Walsh M, Zheng X, Wu Z, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5:13031307. MEDLINE
  • 44
    Li Y, Li X, Zheng X, Wells A, Turka L, Strom T. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5:12981302. MEDLINE
  • 45
    Kimball P, Kerman R, Kahan B. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991; 51:486490. MEDLINE
  • 46
    Schuurman H, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation 1997; 64:3235. MEDLINE
  • 47
    Stepkowski S, Tian L, Napoli K, Ghobrial R, Wang M, Chou T, et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clin Exp Immunol 1997; 108:6368. MEDLINE
  • 48
    Vu M, Qi S, Xu D, Wu J, Fitzsimmons W, Sehgal S, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64:18531856. MEDLINE
  • 49
    Ochiai T, Gunji Y, Nagata M, Komori A, Asano T, Isono K. Effects of rapamycin in experimental organ allografting. Transplantation 1993; 56:1519. MEDLINE
  • 50
    Stepkowski S, Chen H, Daloze P, Kahan B. Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats. Transplant Proc 1991; 23:507508. MEDLINE
  • 51
    Chen H, Wu J, Luo H, Daloze P. Synergistic effect of rapamycin and cyclosporine in pancreaticoduodenal transplantation in the rat. Transplant Proc 1992; 24:892893. MEDLINE
  • 52
    Marquet R, de Bruin RW, Heineman E, Jeekel J. Efficacy of rapamycin in orthotopic small bowel transplantation in the rat. Transplant Proc 1993; 25:26952696. MEDLINE
  • 53
    Chen H, Wu J, Xu D, Luo H, Daloze P. Rapamycin reverses acute heart, kidney, and pancreas allograft rejection and prevents accelerated heart allograft rejection in the rat. Transplant Proc 1993; 25:719720. MEDLINE
  • 54
    Ferraresso M, Wang M, Stepkowski S, Kahan B. Rescue therapy with rapamycin blocks an ongoing process of heart allograft rejection. Transplant Proc 1993; 25:729. MEDLINE
  • 55
    Granger D, Cromwell J, Chen S, Goswitz J, Morrow D, Beierle F, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995; 59:183186. MEDLINE
  • 56
    Almond P, Moss A, Nakhleh R, Melin M, Chen S, Salazar A, et al. Rapamycin: Immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model. Transplantation 1993; 56:275281. MEDLINE
  • 57
    Cohen D, Fisher R, Shapiro J, Goggins W, Tawes J, Mills S, et al. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy. Transplant Proc 1996; 28:25012505. MEDLINE
  • 58
    Granger D, Cromwell J, Canafax D, Matas A. Combined rapamycin and cyclosporine immunosuppression in a porcine renal transplant model. Transplant Proc 1996; 28:984. MEDLINE
  • 59
    Ferraresso M, Knight R, Tu Y, Stepkowski S, Kahan B. Triple combination of cyclosporine, brequinar, and rapamycin prolongs kidney allograft survival in the mongrel dog. Transplant Proc 1994; 26:3028. MEDLINE
  • 60
    Yakimets W, Lakey J, Yatscoff R, Katyal D, Ao Z, Finegood D, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation 1993; 56:12931298. MEDLINE
  • 61
    Knight R, Ferraresso M, Serino F, Katz S, Lewis R, Kahan B. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993; 55:947949. MEDLINE
  • 62
    Collier D, Calne R, Pollard S, Friend P, Thiru S. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23:22462247. MEDLINE
  • 63
    Viklicky O, Zou H, Muller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69:497502. MEDLINE
  • 64
    Hausen B, Boeke K, Berry G, Segarra I, Christians U, Morris R. Suppression of acute rejection in allogeneic rat lung transplantation: A study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18:150159. MEDLINE
  • 65
    Hausen B, Boeke K, Berry G, Christians U, Schuler W, Morris R. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD. Ann Thorac Surg 2000; 69:904909. MEDLINE
  • 66
    Hausen B, Boeke K, Berry G, Segarra I, Benet L, Christians U, et al. Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: Potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation 1999; 67:956962. MEDLINE
  • 67
    Schuurman H, Ringers J, Schuler W, Slingerland W, Jonker M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69:737742. MEDLINE
  • 68
    Hausen B, Gummert J, Berry G, Christians U, Serkova N, Ikonen T, et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: Induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation 2000; 69:488496. MEDLINE
  • 69
    Hausen B, Ikonen T, Briffa N, Berry G, Christians U, Robbins R, et al. Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation 2000; 69:7686. MEDLINE
  • 70
    Schuurman H, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999; 31:10241025. MEDLINE
  • 71
    Cole O, Shehata M, Rigg K. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998; 30:22002203. MEDLINE
  • 72
    Salminen U, Alho H, Taskinen E, Maasilta P, Ikonen T, Harjula A. Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model. Transplant Proc 1998; 30:22042205. MEDLINE
  • 73
    Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000; 97:42854290. MEDLINE
  • 74
    Andoh T, Burdmann E, Fransechini N, Houghton D, Bennett W. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50:11101117. MEDLINE
  • 75
    Di Joseph J, Mihatsch M, Sehgal S. Renal effects of rapamycin in the spontaneously hypertensive rat. Transpl Int 1994; 7:8388. MEDLINE
  • 76
    Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Rapamune (sirolimus) Oral Solution: Medical Officer's Review and Clinical Pharmacology and Biopharmaceutics Review(s). Available at: http://www.fda.gov/cder/foi/nda/99/21083A.htm. Accessed December 28, 2000.
  • 77
    Zimmerman J, Kahan B. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37:405415. MEDLINE
  • 78
    Johnson E, Zimmerman J, Duderstadt K, Chambers J, Sorenson A, Granger D, et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996; 28:987. MEDLINE
  • 79
    MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(suppl B):B101B121. MEDLINE
  • 80
    Brattstrom C, Tyden G, Sawe J, Herlenius G, Claesson K, Groth C. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 1996; 28:985986. MEDLINE
  • 81
    Stepkowski SM, Tian L, Wang ME, Qu X, Napoli K, Kahan BD. Sirolimus in transplantation. Arch Immunol Ther Exp (Warsz) 1997; 45:383390. MEDLINE
  • 82
    Kaplan B, Meier-Kriesche H, Napoli K, Kahan B. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998; 63:4853. MEDLINE
  • 83
    Neumayer HH, Paradis K, Korn A, Jean C, Fritsche L, Budde K, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 1999; 48:694703. MEDLINE
  • 84
    Serkova N, Hausen B, Berry G, Jacobsen W, Benet L, Morris R, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294:323332. MEDLINE
  • 85
    Aspeslet LJ, Yatscoff RW. Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation. Clin Ther 2000; 22(suppl B):B86B92. MEDLINE
  • 86
    Meier Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: Relationship to whole-blood concentrations. Clin Ther 2000; 22(suppl B):B93B100. MEDLINE
  • 87
    Shaw LM, Kaplan B, Brayman KL. Advances in therapeutic drug monitoring for immunosuppressants: A review of sirolimus. Introduction and overview. Clin Ther 2000; 22(suppl B):B1B13. MEDLINE
  • 88
    Johnston A, Holt DW. Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol 1999; 47:339350. MEDLINE
  • 89
    Gallant HL, Yatscoff RW. P70 S6 kinase assay: A pharmacodynamic monitoring strategy for rapamycin; Assay development. Transplant Proc 1996; 28:30583061. MEDLINE
  • 90
    Ferron GM, Pyszczynski NA, Jusko WJ. Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays. Transplantation 1998; 65:12031209. MEDLINE
  • 91
    Ferron GM, Jusko WJ. Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. Pharm Res 1998; 15:18881894. MEDLINE
  • 92
    Dambrin C, Klupp J, Morris R. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000; 12:557562. MEDLINE
  • 93
    Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49:209216. MEDLINE
  • 94
    Kahan BD, Wong RL, Carter C, Katz SH, Von Fellenberg J, Van Buren CT, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999; 68:11001106. MEDLINE
  • 95
    Doyle RL, Hertz MI, Dunitz JM, Loyed JE, Stecenko AA, Wong RL, et al. Safety and pharmacokinetics of RAD in stable lung and heart-lung transplant recipients. Rome: XVIII International Congress of the Transplant Society, 2000:0663.
  • 96
    Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66:10401046. MEDLINE
  • 97
    Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management. Transplantation 2000; 69:20852090. MEDLINE
  • 98
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:10361042. MEDLINE
  • 99
    Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:12521260. MEDLINE
  • 100
    McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression [letter]. Lancet 2000; 355:376377. MEDLINE
  • 101
    Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356:194202. MEDLINE
  • 102
    Gaston RS. Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens. Transplant Proc 1999; 31(suppl):S17S22.
  • 103
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 1999; 68:15261532. MEDLINE
  • 104
    Food and Drug Administration (FDA) Dockets Management. NDA 21-083 Sirolimus Rapamune®. Available at: http://www.fda.gov/ohrms/dockets/ac/99/slides/3529s1a/. Accessed December 28, 2000.
  • 105
    Solez K, Axelsen R, Benediktsson H, Burdick J, Cohen A, Colvin R, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411422. MEDLINE
  • 106
    Kahan BD, Kaplan B, Lorber M, Winkler M, Cambon N, Maca J, et al. Safety and preliminary efficacy of RAD in de novo renal transplant recipients in a multicenter, randomized, double-blind, dose finding study. Rome: XVIII International Congress of the Transplant Society, 2000:0662.
  • 107
    Watson C, Friend P, Jamieson N, Frick T, Alexander G, Gimson A, et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999; 67:505509. MEDLINE
  • 108
    Kneteman NM, Bain V, Babini R, Meeberg G, Shapiro AMJ, Issa S, et al. Sirolimus rescue therapy in liver transplantation. Rome: XVIII International Congress of the Transplant Society, 2000:P0796.
  • 109
    Nishida S, Pinna A, Weppler D, Verzaro R, Levi D, Kato T, et al. Rescue of chronic rejection after liver transplantation with sirolimus. Rome: XVIII International Congress of the Transplant Society, 2000:P0808.
  • 110
    Pappas PA, Weppler D, Pinna AD, Rusconi P, Thompson JF, Jaffe JS, et al. Sirolimus in pediatric gastrointestinal transplantation: The use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. Pediatr Transplant 2000; 4:4549. MEDLINE
  • 111
    Haddad H, MacNeil DM, Howlett J, O'Neill B. Sirolimus, a new potent immunosuppressant agent for refractory cardiac transplantation rejection: Two case reports. Can J Cardiol 2000; 16:221224. MEDLINE
  • 112
    Straatman LP, Coles JG. Pediatric utilization of rapamycin for severe cardiac allograft rejection. Transplantation 2000; 70:541543. MEDLINE
  • 113
    Backman L, Morales JM. Is nonnephrotoxic immunosuppression a possibility? Transplantation 2000; 69(suppl):S27S30.
  • 114
    Fisher NC, Malag M, Gonzlez Pinto I. The clinical impact of nephrotoxicity in liver transplantation. Transplantation 2000; 69(suppl):S18S22.
  • 115
    Halloran PF. Sirolimus and cyclosporin for renal transplantation. Lancet 2000; 356:179180. MEDLINE
  • 116
    Legendre C, Squifflet J-P, Campistol JM, Mourad G, Group FtSERTS. Sirolimus vs cyclosporine: A comparison of lipid parameters over two years. Rome: XVIII International Congress of the Transplant Society, 2000:P0502W.
  • 117
    Blum CB, for the Rapamune US Study Group. Analysis of cholesterol and triglyceride levels in sirolimus-treated transplant recipients. Rome: XVIII International Congress of the Transplant Society, 2000:P0510W.
  • 118
    Levy D, Wilson PW, Anderson KM, Castelli WP. Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. Am Heart J 1990; 119:712717. MEDLINE
  • 119
    Waldmann H. Transplantation tolerance—Where do we stand? Nat Med 1999; 5:12451248. MEDLINE